Repository logo
 

Codon usage optimization in pluripotent embryonic stem cells.

Accepted version
Peer-reviewed

Change log

Authors

Bornelöv, Susanne 
Selmi, Tommaso 
Flad, Sophia 
Dietmann, Sabine 

Abstract

BACKGROUND: The uneven use of synonymous codons in the transcriptome regulates the efficiency and fidelity of protein translation rates. Yet, the importance of this codon bias in regulating cell state-specific expression programmes is currently debated. Here, we ask whether different codon usage controls gene expression programmes in self-renewing and differentiating embryonic stem cells. RESULTS: Using ribosome and transcriptome profiling, we identify distinct codon signatures during human embryonic stem cell differentiation. We find that cell state-specific codon bias is determined by the guanine-cytosine (GC) content of differentially expressed genes. By measuring the codon frequencies at the ribosome active sites interacting with transfer RNAs (tRNA), we further discover that self-renewing cells optimize translation of codons that depend on the inosine tRNA modification in the anticodon wobble position. Accordingly, inosine levels are highest in human pluripotent embryonic stem cells. This effect is conserved in mice and is independent of the differentiation stimulus. CONCLUSIONS: We show that GC content influences cell state-specific mRNA levels, and we reveal how translational mechanisms based on tRNA modifications change codon usage in embryonic stem cells.

Description

Keywords

Codon bias, Differentiation, Stem cell self-renewal, tRNA modifications, Animals, Base Composition, Cell Self Renewal, Codon, Embryonic Stem Cells, Humans, Protein Biosynthesis, RNA, Transfer

Journal Title

Genome Biol

Conference Name

Journal ISSN

1474-7596
1474-760X

Volume Title

20

Publisher

Springer Science and Business Media LLC

Rights

All rights reserved
Sponsorship
Cancer Research Uk (None)
Medical Research Council (MR/M01939X/1)
Medical Research Council (MC_PC_12009)
This work was funded by Cancer Research UK (CR-UK) and the Medical Research Council (MRC). Parts of this research in Michaela Frye's laboratory was supported by core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute.